Stage III/IV Mantle Cell Lymphoma
1 clinical trials · Condition
◉ Watch Stage III/IV Mantle Cell Lymphoma
| Record | Firm | Date |
|---|---|---|
| Anti-CD22 CAR-T Therapy for CD19-refractory or Resistant Lymphoma Patients (NCT02721407) | Xinqiao Hospital of Chongqing | 2016-03-01 |
Track Stage III/IV Mantle Cell Lymphoma automatically
Every clearance here is in the API, with alerts when new ones post.